HIV-1 DNA predicts disease progression and post-treatment virological control

dc.contributor.authorWilliams, James P.
dc.contributor.authorHurst, Jacob
dc.contributor.authorStöhr, Wolfgang
dc.contributor.authorRobinson, Nicola
dc.contributor.authorBrown, Helen
dc.contributor.authorFisher, Martin
dc.contributor.authorKinloch, Sabine
dc.contributor.authorCooper, David A.
dc.contributor.authorSchechter, Mauro
dc.contributor.authorTambussi, Giuseppe
dc.contributor.authorFidler, Sarah
dc.contributor.authorCarrington, Mary
dc.contributor.authorBabiker, Abdel
dc.contributor.authorWeber, Jonathan
dc.contributor.authorKoelsch, Kersten K.
dc.contributor.authorKelleher, Anthony D.
dc.contributor.authorPhillips, Rodney E.
dc.contributor.authorFrater, John
dc.contributor.authorMiró Meda, José M. (José María), 1956-
dc.contributor.authorGatell, José M.
dc.contributor.authorSPARTAC Trial Investigators
dc.date.accessioned2017-11-02T12:27:38Z
dc.date.available2017-11-02T12:27:38Z
dc.date.issued2014-09-12
dc.date.updated2017-11-02T12:27:38Z
dc.description.abstractIn HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec649160
dc.identifier.issn2050-084X
dc.identifier.pmid25217531
dc.identifier.urihttps://hdl.handle.net/2445/117328
dc.language.isoeng
dc.publishereLife Sciences
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.7554/eLife.03821
dc.relation.ispartofeLife, 2014, vol. 3, p. e03821
dc.relation.urihttps://doi.org/10.7554/eLife.03821
dc.rightscc-by (c) Williams, James P. et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationVIH (Virus)
dc.subject.classificationAntiretrovirals
dc.subject.classificationMalalties infeccioses
dc.subject.classificationAssaigs clínics
dc.subject.otherHIV (Viruses)
dc.subject.otherAntiretroviral agents
dc.subject.otherCommunicable diseases
dc.subject.otherClinical trials
dc.titleHIV-1 DNA predicts disease progression and post-treatment virological control
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
649160.pdf
Mida:
1.19 MB
Format:
Adobe Portable Document Format